Last updated: July 16, 2026
Allergan, Inc. sued Alembic Pharmaceuticals Limited in the US District Court for the District of New Jersey in case 1:25-cv-06986 in a Hatch-Waxman-style patent dispute. The filing date and the underlying patents, asserted claims, Orange Book listing, ANDA/Biologics context, and any Paragraph IV allegations are not provided in the available information, so no accurate claim-by-claim or patent-by-patent infringement/validity analysis can be produced.
What case is Allergan, Inc. v. Alembic Pharmaceuticals Limited (1:25-cv-06986) about?
Answer: It is a federal patent litigation filing by Allergan against Alembic (district court case number 1:25-cv-06986). The specific drug, the patents asserted, the legal theories (infringement, invalidity, unenforceability), and the procedural posture are not available from the provided inputs, so the scope of the dispute cannot be determined.
Which court and parties are involved?
- Court: US District Court, District of New Jersey
- Case number: 1:25-cv-06986
- Plaintiff: Allergan, Inc.
- Defendant: Alembic Pharmaceuticals Limited
What patents are at issue in Allergan v. Alembic (1:25-cv-06986)?
Answer: Not stated in the provided information.
How to identify the asserted patent estate (what would normally be checked)
In this type of action, the asserted estate is typically identified through:
- the complaint’s list of asserted Orange Book patents and patent numbers,
- claim charts or infringement allegations,
- any amendments to pleadings and patent schedules,
- court docket entries listing the patents and case schedule.
No such patent identifiers are included in the available content, so no “how many patents,” “which claims,” or “expiration timeline” analysis can be produced.
What is the litigation timeline for 1:25-cv-06986?
Answer: Not determinable from the provided information.
Procedural milestones normally required for a defensible timeline
A complete timeline would require docket dates for:
- complaint filed date,
- service and answer deadlines,
- motions to dismiss and any claim construction scheduling,
- expert deadlines,
- Markman proceedings (if any),
- trial dates or settlement conferences.
Those docket milestones are not included in the provided inputs.
Has Alembic filed any Paragraph IV certification or FDA challenge connected to 1:25-cv-06986?
Answer: Not stated.
What Orange Book status would be needed
To analyze Paragraph IV exposure, you must know:
- the relevant FDA application type (ANDA),
- the Orange Book drug product and listed patents,
- the certifications (Paragraph IV vs other),
- whether Allergan is asserting benefits of 180-day exclusivity or other statutory periods.
None of these items are available in the provided information, so the FDA exclusivity and Paragraph IV posture cannot be analyzed.
What is Allergan’s patent infringement theory in this case?
Answer: Not stated.
What would be analyzed if claims and product details were available
A standard infringement analysis would map:
- which product Alembic is accused of making/using/selling,
- the specific asserted claims,
- the infringement method (literal vs doctrine of equivalents),
- manufacturing and labeling allegations used to support direct or induced infringement.
No asserted claims or product details are present, so infringement analysis cannot be completed.
What defenses might Alembic raise, and how strong are they?
Answer: Defenses cannot be assessed because the complaint’s asserted patents, claims, and Allegations are not provided.
Defense categories typically seen in Hatch-Waxman
- invalidity (anticipation, obviousness, indefiniteness, lack of written description),
- non-infringement,
- unenforceability (inequitable conduct),
- jurisdiction/venue and procedural issues.
Without the patent numbers, claim sets, or the allegations pleaded, strength scoring would be ungrounded.
What is the status of motions and discovery in 1:25-cv-06986?
Answer: Not stated.
Why procedural status matters for business decisions
The business impact depends on:
- whether there are pending dispositive motions,
- whether the court entered a schedule that signals urgency or a stay,
- whether there is a possibility of early resolution (settlement or consent judgment).
No docket status data is included in the provided information.
Has there been a settlement, consent judgment, or licensing agreement tied to 1:25-cv-06986?
Answer: Not stated.
What would be required to analyze commercial impact
A settlement analysis depends on:
- effective date of any license,
- permitted launch dates,
- design-around commitments,
- ongoing royalty terms (if any),
- stipulations on patent validity/infringement for entry timing.
No settlement terms are present in the provided inputs.
How does this case affect the competitive landscape for Allergan products vs Alembic?
Answer: Not determinable because the underlying drug/patents are not identified.
Revenue and entry risk framework (what must be known)
To quantify exposure you need:
- which branded drug or line item is being targeted,
- the relevant exclusivity and patent expiration dates,
- whether Alembic is seeking a specific strength/formulation,
- whether the asserted patents block generic entry or delay only certain SKUs.
None of these inputs are available, so no commercial risk analysis can be produced.
Key Takeaways
- Case identified: Allergan, Inc. v. Alembic Pharmaceuticals Limited, 1:25-cv-06986 in the District of New Jersey.
- Substance not available: asserted patents, FDA/ANDA context, Paragraph IV certifications, and procedural status are not provided in the available information.
- No defensible analysis: without the complaint’s patent list and the accused product/regulatory posture, litigation strengths, timelines, and entry risk cannot be calculated.
FAQs
-
What is the district court docket number for Allergan v. Alembic?
1:25-cv-06986.
-
Which companies are parties to the case?
Allergan, Inc. (plaintiff) and Alembic Pharmaceuticals Limited (defendant).
-
Is this case an ANDA Paragraph IV challenge?
Not stated in the provided information.
-
Which patents does Allergan assert in 1:25-cv-06986?
Not stated in the provided information.
-
What is the current procedural status of 1:25-cv-06986?
Not stated in the provided information.
References
- US District Court, District of New Jersey. Case 1:25-cv-06986 (Allergan, Inc. v. Alembic Pharmaceuticals Limited).
